te Cipla: Today Latest News, Photos, Videos about Cipla - Zee Business

हिंदी में पढ़ें

Cipla

Cipla Shares Slip as Executive Vice-Chair Steps Down | Stock Market News

Cipla Shares Slip as Executive Vice-Chair Steps Down | Stock Market News

Mon, Jan 29, 2024

Shares of Cipla dipped 3% as Samina Hamied resigned as executive vice-chair, transitioning to a non-executive director role. The move is part of a broader strategy to professionalize Cipla's management, akin to conglomerates like the Tata Group. Balram Bhargava was appointed as an additional independent director, bringing over 35 years of global public health leadership experience.

Cipla posts better-than-estimated Q3 results; stock hits all-time high

Cipla posts better-than-estimated Q3 results; stock hits all-time high

Tue, Jan 23, 2024

As of 9:56 a.m., shares of drug major Cipla traded 6.85 per cent or Rs 89.85, higher on the BSE at Rs 1,402.45 apiece. The market capitalisation of the company at around the same time stood at Rs 1,13,227.87 crore.

Cipla Q3 results: 32% rise in net profit to Rs 1,056 crore

Cipla Q3 results: 32% rise in net profit to Rs 1,056 crore

Mon, Jan 22, 2024

The Mumbai-based company had posted a consolidated net profit of Rs 801 crore in the year-ago period, Cipla Ltd said in a statement. Total revenue from operations in the third quarter of the current fiscal rose to Rs 6,604 crore as compared with Rs 5,810 crore in the year-ago period.

TRENDING NOW

Pharma stocks in focus: Cipla, Zydus Wellness, Torrent Pharma surge up to 5% after healthy Q1 results – brokerages recommend this

Pharma stocks in focus: Cipla, Zydus Wellness, Torrent Pharma surge up to 5% after healthy Q1 results – brokerages recommend this

Mon, Aug 01, 2022

Despite healthy Q1FY23 earnings, the pharma major Sun Pharma shares were seen trading flat in the early morning and later declined more than 3 per cent to Rs 913 per share on the BSE intraday on Monday.

Q1 Results FY2023: NTPC, Cipla, Emami, Exide Industries, EIH announce June quarter results - highlights

Q1 Results FY2023: NTPC, Cipla, Emami, Exide Industries, EIH announce June quarter results - highlights

Fri, Jul 29, 2022

NTPC Q1 Results FY2023: State-owned NTPC on Friday posted a more than 15 per cent increase in consolidated net profit to Rs 3,977.77 crore in the June quarter on the back of higher income

brokerage report of this week brokerage bullish on top 5 pharma stocks check latest list here

brokerage report of this week brokerage bullish on top 5 pharma stocks check latest list here

Fri, Jul 22, 2022

Global Brokerage report on pharma stocks of this week. In this video know the full list and target price to make a buy choice.

Cipla to invest Rs 26 crore in GoApptiv to raise stake to 22%

Cipla to invest Rs 26 crore in GoApptiv to raise stake to 22%

Tue, Jun 28, 2022

Pharma company Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said on Monday.

Global View: Hindustan Unilever, Cipla, Infosys and JSW Steel shares can give 12-35% return – know what brokerages say

Global View: Hindustan Unilever, Cipla, Infosys and JSW Steel shares can give 12-35% return – know what brokerages say

Mon, Jun 06, 2022

Indian markets on Monday made a gap-down opening as Nifty opened below 16550 levels and Sensex slipped over 100 points. Whereas Nifty Midcap 100 also declined by 0.1 per cent at open.

Cipla Share Price: After company reports healthy March quarter numbers, brokerages turn bullish on stock; recommend buy

Cipla Share Price: After company reports healthy March quarter numbers, brokerages turn bullish on stock; recommend buy

Wed, May 11, 2022

Cipla Share Price:Brokerages are bullish on the Cipla shares and expects a 28 per cent upside in this stock. A healthy March quarter results will likely act as a trigger for the upside, they opined.

Q4 Results 2022: Cipla, Max Financial Services, Torrent Power, Ajanta Pharma, Welspun India declare March quarter results; see key highlights

Q4 Results 2022: Cipla, Max Financial Services, Torrent Power, Ajanta Pharma, Welspun India declare March quarter results; see key highlights

Tue, May 10, 2022

Cipla Q4 results 2022: Drug major Cipla on Tuesday said its consolidated profit after tax declined by 12 per cent to Rs 362 crore for the fourth quarter ended March 2022

Cipla Q4 results 2022 Preview: March quarter results on Tuesday; here is what to expect from company earnings, stock

Cipla Q4 results 2022 Preview: March quarter results on Tuesday; here is what to expect from company earnings, stock

Mon, May 09, 2022

Pharma major Cipla's will announce its fourth-quarter results on Tuesday. Senior Research Analyst at Zee Business Kushal Gupta's brings his earnings estimates in this report.

Cipla Q4 Results Preview: How will be the results? Watch Here

Cipla Q4 Results Preview: How will be the results? Watch Here

Mon, May 09, 2022

Tomorrow the results of Nifty company Cipla are going to come. How will be Cipla's results in Q4? How will Cipla perform? Know the prediction of the results from Kushal Gupta.

Pharma Stocks in Focus: Alkem Lab & IPCA Lab among 4 stocks that may benefit most from 10.8% hike in drugs from April 1

Pharma Stocks in Focus: Alkem Lab & IPCA Lab among 4 stocks that may benefit most from 10.8% hike in drugs from April 1

Thu, Mar 31, 2022

The National Pharma Pricing Authority (NPPA) has approved 10.8% hike in over 800 essential drugs starting April 1,2022. This is the biggest hike by NPPA in the last 10 years.

DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer

DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer

Wed, Mar 30, 2022

Directorate General of GST Intelligence (DGGI) which works under the aegis of the Ministry of Finance has taken action against many big pharma companies in the country for not filing Goods and Services Tax (GST). The pharma giants included are Dr. Reddys Laboratories, Glenmark, Aurobindo Pharma, Mylan and Cipla, as reported by Zee Business’s Tarun Sharma.

Value Pick: Strong India franchise, rich product pipeline makes Cipla shares lucrative; brokerages see 15% upside

Value Pick: Strong India franchise, rich product pipeline makes Cipla shares lucrative; brokerages see 15% upside

Mon, Mar 14, 2022

Several brokerages are betting big on Cipla Limited stocks on the back of robust fundamentals, strong product pipeline in US and improved business outlook. They see an upside of up to 15 per cent in the stock price and find the current valuations attractive.

Technical Check: Long bullish candle on weekly charts puts this pharma stock on buyers radar; see 20% upside in 6-9 months

Technical Check: Long bullish candle on weekly charts puts this pharma stock on buyers radar; see 20% upside in 6-9 months

Mon, Mar 14, 2022

The recent rally despite muted global cues resulted in a breakout which puts Cipla on buyers' radar.

M-Cap: Equity market capitalisation drops to six-month low in February

M-Cap: Equity market capitalisation drops to six-month low in February

Mon, Feb 28, 2022

The total equity market capitalisation (m-cap) has dropped to a six-month low of Rs 2,52,39,045.09 crore in February 2022.

Cipla shares gain post q3 result as HDFC securities, ICICI Securities see upside of up to 19%

Cipla shares gain post q3 result as HDFC securities, ICICI Securities see upside of up to 19%

Thu, Jan 27, 2022

Brokerage house ICICI Securities and HDFC securities have maintained buy rating on Cipla despite the pharma major witnessed marginal decline in net profit.

Global View: Maruti Suzuki, Cipla and United Spirits could give 17-20% return in 1 year

Global View: Maruti Suzuki, Cipla and United Spirits could give 17-20% return in 1 year

Thu, Jan 27, 2022

Indian market is likely to retest crucial support levels on Thursday, tracking weak global cues

Naina Lal Kidwai resigns as independent director from Cipla board

Naina Lal Kidwai resigns as independent director from Cipla board

Wed, Jan 26, 2022

Drug major Cipla on Wednesday said Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022

Cipla Q3FY22 Results: PAT stands at Rs 757 crore, revenue grows to Rs 5,479 crore

Cipla Q3FY22 Results: PAT stands at Rs 757 crore, revenue grows to Rs 5,479 crore

Tue, Jan 25, 2022

Most of the analysts had estimated that the profit would show a dip year-on-year YoY, and revenue may jump marginally by around 2 per cent.

Cipla Q3FY22 Preview: Pharma major likely to report muted earnings, profit may slip up to 12% YoY

Cipla Q3FY22 Preview: Pharma major likely to report muted earnings, profit may slip up to 12% YoY

Mon, Jan 24, 2022

The pharmaceutical major Cipla is likely to report muted third quarter earnings for the financial year 2021-22, most of the brokerage houses and analysts predict in their results preview.

Global View: ICICI Bank, Bandhan Bank, Cipla and Container Corp could give 15-40% return in long term

Global View: ICICI Bank, Bandhan Bank, Cipla and Container Corp could give 15-40% return in long term

Mon, Jan 24, 2022

The Indian markets are likely to witness some volatility on Monday tracking weak global cues, but there will be stock-specific action in which global brokerage came out with their reports on business development, or earnings outlook.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x